MDACC Study No:ID02-321 ( NCT No: NCT00102622)
Title:A Phase I/II RANDOMIZED Study of Intraperitoneal tgDCC-E1A and Intravenous Paclitaxel in Women with Platinum-Resistant Ovarian Cancer
Principal Investigator:Naoto Ueno
Treatment Agent:E1A; Taxol
Study Status:Terminated
Study Description:The goal of this clinical research study is to find the highest safe dose of
intraperitoneal tgDCC-E1A that can be given in combination with paclitaxel as a
treatment for patients with recurrent, platinum-resistant ovarian cancer. How
the cancer responds to this treatment will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Ovary
Phase of Study:Phase I/Phase II
Treatment Agents:E1A
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:Not applicable. This is an outpatient study.
Supported By:N/A
Return Visit:Weekly for six treatments. An additional six treatments of therapy may be added
if disease is stable or responding to treatment after restaging.
Home Care:None.

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Naoto Ueno
Dept:Gynecologic Oncology
For Clinical Trial Enrollment:713-792-7310
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults